Access to bone densitometry increases general practitioners’ prescribing for osteoporosis in steroid treated patients

Background: Availability of access to bone densitometry in the UK varies widely and there are concerns as to appropriate prescribing. Studies suggest inadequate use of osteoporosis prophylaxis in steroid users, despite recent guidelines. Objective: To examine in a case-control study whether access t...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 63; no. 2; pp. 183 - 186
Main Authors Dolan, A L, Koshy, E, Waker, M, Goble, C M
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and European League Against Rheumatism 01.02.2004
BMJ
BMJ Publishing Group Ltd
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: Availability of access to bone densitometry in the UK varies widely and there are concerns as to appropriate prescribing. Studies suggest inadequate use of osteoporosis prophylaxis in steroid users, despite recent guidelines. Objective: To examine in a case-control study whether access to bone densitometry affects GPs’ osteoporosis prescribing in high risk steroid users. Method: 10 general practices were included, five from primary care trusts (PCTs) with access to bone densitometry and five with limited access. Patients receiving prednisolone for >3 months were identified by database search. Patients receiving no prophylaxis other than calcium and vitamin D (Ca/D) were subsequently included. Appropriate patients in five practices were offered DXA scan (cases) and review. Patients in practices without access to scans (controls) were reviewed. GPs’ opinions leading to treatment were sought by structured questionnaire. Results: 132 (0.12%) patients were receiving prednisolone for ⩾3 months, but no osteoporosis prophylaxis other than Ca/D. Pre-study prophylaxis ranged from 18 to 36%. Of 48 patients scanned, 21 (44%) were abnormal and 18 (38%) received new treatment. 13/44 (30%) controls received new treatment. 10/21 (48%) with abnormal scans started a bisphosphonate, compared with 7/44 (16%) controls (RR = 3, p = 0.004). No difference in risk factors for fracture was found in treated and untreated controls. Conclusions: GPs were three times more likely to start potent osteoporosis treatment after abnormal scans than GPs relying on clinical information. In practice, risk factors were not adequately assessed. Database searches may identify patients needing osteoporosis prophylaxis; however, DXA enables more appropriate patient treatment.
Bibliography:Correspondence to:
 Dr A L Dolan
 Department of Rheumatology, Queen Elizabeth Hospital, Stadium Road, London SE18, UK; ldolan@btinternet.com
local:0630183
PMID:14722208
istex:1FF1D3402AC178E55D177F554AA7A0FA64C4A4D3
href:annrheumdis-63-183.pdf
ark:/67375/NVC-D27NDNH0-L
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.2003.006130